210 results about "Viral gene" patented technology

The disclosure relates to block copolymer nanoparticles for therapeutic delivery of nucleic acids, and methods therefor. More particularly, the invention relates to polymer nanoparticles, such as reversible addition-fragmentation chain transfer (RAFT) polymer compositions, for delivering miRNAs.

The disclosure relates to block copolymer nanoparticles for therapeutic delivery of nucleotides, and methods therefor. More particularly, the invention relates to polymer nanoparticles, such as reversible addition-fragmentation chain transfer (RAFT) polymer compositions, for delivering miRNAs.

The invention provides a rapid processing method for HPV (human papillomavirus) gene sequence data. The method relates to the technical field of data processing, and comprises the following steps: acquiring and integrating HPV sequence data, host transcriptome data and clinical association data to form a comprehensive input matrix; performing feature screening on the comprehensive input matrix by adopting a bee colony optimization algorithm based on reinforcement learning to obtain an optimal feature subset; according to the bee colony optimization algorithm, global search of the bee colony algorithm is combined with a dynamic decision-making mechanism of reinforcement learning, and a feature selection strategy is dynamically adjusted; and constructing an HPV subtype accurate typing and variation detection model based on multi-task deep learning, performing deep coding and weighted fusion on the optimal feature subset through an unstable attention mechanism, and outputting two key prediction results of subtype probability and mutation site probability. According to the method, the accuracy and biological interpretability of virus typing and variation detection are improved, and efficient extraction and multi-task accurate recognition of high-dimensional features are realized.

The invention discloses a primer for detecting and distinguishing genotypes of avian infectious bronchitis viruses and application, and belongs to the technical field of biological detection. The primer combination comprises a universal primer and a probe group I for detecting an IBV total group, a specific primer and a probe combination II for detecting a GI-19 genotype, and a specific primer and a probe combination III for detecting a GVI-1 genotype, and nucleotide sequences are respectively shown as SEQ ID NO.1-9; different fluorophores are respectively marked at 5'ends of each group of probes, and corresponding quenching groups are marked at 3 'ends of each group of probes. The primer combination provided by the invention has high specificity and high sensitivity, rapid detection of the IBV and accurate distinguishing of main epidemic genotypes (GVI-1 and GI-19) can be completed in a single reaction, complex sequencing and analysis steps in a traditional method are omitted, the detection efficiency is greatly improved, and the primer combination has a good application prospect. And a convenient tool is provided for farm epidemic situation monitoring and clinical diagnosis.

The application discloses a method for creating a new strain of Carassius auratus gibelii with resistance to Cyprinid herpesvirus 2 (CyHV2) infection, and the method is characterized in that a gene editing technology is used to target knockout gsdf-a a gene and gsdf-b a gene, and an experimental animal infection model of a homozygous knockout strain of the gene obtained by the technology is established. gsdf Results of the experimental animal infection model show that gsdf the CyHV2 infection resistance of the CyHV2 gene knockout Carassius auratus gibelii is significantly enhanced, the histopathological damage of the Carassius auratus gibelii after being infected with the virus is reduced, the expression of a virus protein ORF47 in liver tissue of the Carassius auratus gibelii is reduced, and the transcription level of a virus gene orf46r is significantly reduced. The new strain of Carassius auratus gibelii created by the method can avoid exogenous gene pollution, and has the advantages that the CyHV2 infection resistance of the Carassius auratus gibelii is significantly enhanced.

This invention provides a dengue / Zika virus genetically engineered vaccine and its application. The dengue / Zika virus vaccine comprises an open reading frame encoding envelope protein domain III (EDIII) and the non-structural protein NS1, and displays EDIII monomers in the delivery vector shell. Immunization with this vaccine primarily induces a type-specific antibody response, reducing the production of cross-antibodies and thus effectively avoiding or eliminating the risk of antibody-dependent enhancement of infection (ADE). This vaccine can be used to prevent dengue virus and Zika virus infection.

The present application relates to the technical field of knowledge graph, in particular to a multi-task hepatitis B drug screening method and system based on knowledge graph assistance, comprising the following steps: based on hepatitis B virus genotype sequence data recorded over time, patient drug use records and drug sensitivity. In the present application, multi-dimensional dynamic time series data such as virus genotype sequence data, patient drug use records and drug sensitivity are integrated, the interaction events between entities are marked by time stamp, the dynamic characteristics such as virus variation track and drug efficacy change are embedded in the graph node attributes, so that the knowledge representation can reflect the time dependence in the real scene. Based on biological pathway annotation information and protein interaction data, the hyperedge connection multi-entity set is defined, the limitation of traditional knowledge graph which only supports binary relationship is expanded, the drug combination and multi-target synergistic mechanism are explicitly modeled, and the misjudgment of combination effect caused by the simplification of interaction relationship is avoided.

The present application relates to the field of molecular biology, in particular to a primer probe composition, kit and detection method for 23 human papilloma virus genotyping detection, wherein the hydrolysis probe and molecular beacon probe are respectively designed in two different regions of HPV gene sequence E6 and L1, and the fluorescence collection point in the amplification stage is set in the high-temperature denaturation stage, so that the detection in the amplification stage and the melting curve stage is independent and does not interfere with each other, thereby realizing the combined use of real-time fluorescent PCR amplification detection technology and melting curve technology; the technology improves the single-well detection target flux of fluorescent PCR analysis technology, reduces the detection cost, and provides a more optimal detection method for HPV multiplex fluorescent PCR genotyping detection.

The application relates to the technical field of biological medicine, and particularly discloses a fish rhabdovirus recombinant adenovirus vector vaccine and a preparation method and application thereof. The recombinant adenovirus vaccine carrying the M gene of the SCRV virus is prepared by using a replication-defective recombinant adenovirus vector, and the preparation method comprises the following steps: mandarin fish rhabdovirus M gene cloning, construction of a Pshuttle-CMV-ECMV vector with a target gene SCRV-M, obtaining of a SCRV-M recombinant adenovirus plasmid, screening of the SCRV-M recombinant adenovirus, and preparation of the SCRV-M recombinant adenovirus vaccine. The SCRV-M recombinant adenovirus vaccine prepared by the application can be used for immunoprophylaxis of SCRV virus infection in the juvenile fish stage through a soaking mode, the SCRV-M recombinant adenovirus vaccine has passed an animal safety test, and has a wide application prospect in the prevention and control of fish rhabdovirus.

The present invention relates generally to compositions, systems and methods for modulating hepatitis B virus (HBV) by targeting gene repression. In particular, the present invention provides an epigenetically modified DNA targeting system, such as a CRISPR-Cas / guide RNA (gRNA) system, for transcriptional repression of hepatitis B virus genes to promote cell phenotypes that lead to reduced HBV infection. In some embodiments, the epigenetically modified DNA targeting systems of the present invention bind to or target a target site of at least one gene in the hepatitis B virus DNA sequence or a regulatory element thereof in a cell. In some aspects, the systems provided herein relate to transcriptional repression of one or more hepatitis B virus genes and / or regulatory elements thereof. In some aspects, the invention also provides methods and uses associated with the provided compositions, such as in repression of hepatitis B virus replication and expression associated with hepatitis B infection.

The invention belongs to the field of veterinary virology, and discloses a bovine ephemeral fever virus strain and reverse genetic application thereof, and the reverse genetic steps are as follows: taking pCI plasmid as a skeleton to prepare plasmid for expressing a complete genome of bovine ephemeral fever virus; the method comprises the following steps: respectively preparing auxiliary plasmids for expressing an N protein gene, a P protein gene, an L protein gene and a G protein gene of the bovine ephemeral fever virus by taking pCAGGS plasmids as a skeleton, co-transfecting BHK-21 cells by using the five plasmids, and culturing the cells to obtain the rescued bovine ephemeral fever virus. The rescued bovine ephemeral fever virus has no obvious difference from the reproductive capacity of the parent virus, and the genome is still stable after 10 generations of continuous passage in BHK-21 cells. The invention provides methodological support for genetic modification of the bovine ephemeral fever virus, and has an application prospect.

The invention discloses application of mitoxantrone in preparation of an anti-rabies virus drug, reveals that clinical anti-tumor and immunosuppression drug mitoxantrone has remarkable anti-rabies virus activity for the first time, and opens up a new application field for mitoxantrone. The rigorous in-vitro and in-vivo tests prove that the mitoxantrone can inhibit virus replication in a dose-dependent manner, reduce virus gene and protein expression and remarkably improve the survival rate of infected mice in an animal model. The invention provides a new clinical application approach for mitoxantrone, provides a powerful candidate drug and a brand-new technical scheme for anti-rabies virus drugs, and has important practical significance and clinical application prospects for coping with rabies which is a major public health threat.

The invention belongs to the technical field of virus and gene engineering, and particularly relates to an expression vector of a respiratory syncytial virus (RSV) ON1 genotype consensus sequence strain and an editing strain, a reverse genetic manipulation system and an application of the reverse genetic manipulation system of the respiratory syncytial virus ON1 genotype consensus sequence strain and the editing strain of the RSV ON1 genotype consensus sequence strain and the editing strain of the respiratory syncytial virus ON1 genotype consensus sequence strain. According to the invention, an RSV-ON1 genotype consensus sequence strain is firstly constructed and saved, on the basis, 72 nucleotides which are repeatedly inserted into a G gene of the consensus sequence strain are removed through a gene editing technology, and two strains with different virus G gene sequences are obtained. According to the invention, through construction of RSV infectious clone edited by RSV-ON1 genotype G gene and rescue of the two strains, a fast, simple and accurate RSV reverse genetic system is constructed, and the RSV reverse genetic system can be applied to research on RSV in-vitro virus replication mechanism and pathogenesis and neutralizing antibody immune escape. A etiological technical platform is provided for research, development and evaluation of RSV vaccines, antibodies, drugs and the like.

The invention discloses a porcine epidemic diarrhea virus G2c genotype strain as well as a separation method and application thereof. Aiming at the current epidemic PEDV variant strain, the genetic variation rule of the epidemic strain is clarified by carrying out virus separation, identification and pathogenicity analysis, and the method has important significance on epidemiology, vaccine development and the like of the PEDV. Specifically, an applicant successfully separates a PEDV strain capable of realizing stable passage propagation in Vero-CCL81 cells from intestinal contents of diarrhea piglets collected from a pig farm of Jiangpermanent Province in Hunan, the PEDV strain is identified and determined as a porcine epidemic diarrhea virus G2c subtype, the PEDV strain is named PEDV CH / HNJY / 2025, the PEDV strain is preserved in China General Microbiological Culture Collection Center on December 11, 2025, and the preservation number of the PEDV strain is CGMCC NO. The preservation number is CGMCC (China General Microbiological Culture Collection Center)

The invention provides an application of cudrania tricuspidata polysaccharide in preparation of a medicine for treating or preventing HCMV infection, the cudrania tricuspidata polysaccharide ZGs-1 shows a remarkable inhibition effect on expression of immediate early protein IE1 / 2 and early protein p52 and copy numbers of virus genes UL123, UL44 and UL32 in a plurality of key links of HCMV infection, and has definite antiviral activity. Due to the natural source characteristic of the cudrania tricuspidata polysaccharide ZGs-1, the cudrania tricuspidata polysaccharide ZGs-1 is high in safety and low in cytotoxicity, and the cudrania tricuspidata raw material is easy to obtain, so that a candidate drug or functional component with remarkable potential is provided for preventing and treating the HCMV, and the cudrania tricuspidata polysaccharide ZGs-1 has a good development prospect and application value.

A nonviral gene therapy delivers DNA that allows cells to produce proteins such as their own growth factors in culture media. Lipid nanoparticles provide an effective delivery mechanism into a target cell. By encapsulating plasmid DNA encoding the growth factors with inducible promoters into lipid nanoparticles (LNPs), target cells create their own growth factors reducing a need for expensive growth factors from external sources. DNA expression lasts for several days reducing the amount of reagent needed. The plasmid DNA is more stable than mRNA and proteins, therefore reducing logistical challenges.

The invention relates to a method, uses, a system, and a kit for detecting a human papillomavirus (HPV) genotype associated with the development of cervical, oral, or anogenital cancer in a subject and for determining the HPV genotype or genotypes thus detected in the same. Additionally, the present invention relates to uses of direct and / or reverse amplicons or primers generated by multiplex real-time PCR comprising a molecular tag for identifying a marker of human papillomavirus genotypes 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and / or 68.

The invention discloses a kit for identifying a G2b gene subtype of a porcine epidemic diarrhea virus and application of the kit, and belongs to the field of virus nucleic acid detection. Through gene comparison, primers and probes are designed at specific sequence positions of the PEDV G2b gene subtype, and quantitative PCR identification detection can be directly carried out through an LNA technology. The detection method only comprises two steps of nucleic acid extraction and one-step fluorescent RT-PCR reaction, can complete identification within 2 hours at the soonest, has the characteristics of good specificity, high sensitivity and good stability, can rapidly, simply, conveniently and efficiently identify and detect PEDV G2b subtype nucleic acid, is low in cost and short in period, is especially suitable for high-throughput detection, and can be widely applied to detection of PEDV G2b subtype nucleic acid. And the method has important significance on rapid identification of PEDV G2b gene subtype strains.

The invention provides a norovirus genome splicing method and device, a medium and a product. The method comprises the following steps: acquiring a norovirus gene database, wherein the norovirus gene database comprises a non-structural protein coding region sub-library and a capsid protein coding region sub-library; obtaining original sequencing data; performing quality control on the original sequencing data to obtain screened sequencing data; comparing and assembling the screened sequencing data with the non-structural protein coding region sub-library, and determining at least one first recombinant coding region; and comparing and assembling the screened sequencing data with the capsid protein coding region sub-library, and determining at least one second recombinant coding region, and splicing the at least one first recombinant coding region and the at least one second recombinant coding region to obtain a recombinant genome sequence. Through the technical scheme disclosed by the invention, efficient and accurate splicing of the recombinant norovirus genome sequence is realized, and the assembly accuracy and efficiency of the recombinant norovirus genome sequence are improved.

The invention belongs to the technical field of veterinary vaccines, and particularly relates to an orf virus ORF114 or ORF117 gene deleted strain as well as a preparation method and application thereof. The orf virus ORF114 gene deleted strain is obtained by deleting ORF114 on the basis of an orf virus wild strain, and the orf virus ORF117 gene deleted strain is obtained by deleting ORF117 on the basis of the orf virus wild strain. According to the preparation method, on the basis of an ORFV-CF15 strain (ORFV 2015 strain), ORF114 and ORF117 genes of the ORFV-CF15 strain are deleted by using a gene recombination combined Cre-LoxP system, and two orf gene deleted strains are constructed and screened, and the orf virus ORF114 or ORF117 gene deleted strains have the characteristics of low toxicity, good proliferation and enhancement of Th1 type immune response, and can be used as orf gene engineering vaccine candidate strains.

The invention provides a fluorescent quantitative PCR (polymerase chain reaction) detection primer, a kit and a method for a novel variable chalmavirus VP gene, and belongs to the technical field of virus detection. A specific primer is designed and synthesized according to a conserved sequence of a VP gene of the novel variant chalmavirus, a recombinant plasmid is constructed, then the recombinant plasmid is used as a standard substance to establish a standard curve, a real-time fluorescent quantitative PCR detection system aiming at the novel variant chalmavirus is constructed, and specific detection of the novel variant chalmavirus is realized. The detection method can be used for quantitatively detecting the novel variant chalmavirus in the to-be-detected sample, and has the characteristics of high speed, high sensitivity, strong specificity and the like; the method provides a key technical support for molecular epidemiological investigation of the Sepamavirus in animal populations, is helpful for realizing early screening of infected individuals and timely blocking of virus transmission, and has important practical significance for guaranteeing population health and maintaining high mountain ecosystem stability.

The present invention provides compositions and methods for novel digital PCR (dPCR) assay designs (droplet digital or other systems) for the detection and quantification of multiple Hepatitis B virus (HBV) gene targets. The compositions and methods can further include a non-extendible blocker oligonucleotide to reduce nonspecific inter-amplicon extension.

The present application relates to the field of biomedicine, and provides an epigenetic editing tool for targeting a hepatitis B virus gene and a use thereof.

The application discloses application of siRNA for targeting and inhibiting rabies virus G gene and / or L gene in preparation of a medicine for inhibiting rabies. Furthermore, the application provides siRNA-G for targeting and inhibiting rabies virus G gene and siRNA-L for targeting and inhibiting rabies virus L gene, wherein the nucleotide sequence of the sense strand of the siRNA-G is shown as SEQ ID NO:1, the nucleotide sequence of the antisense strand of the siRNA-G is shown as SEQ ID NO:2; the nucleotide sequence of the sense strand of the siRNA-L is shown as SEQ ID NO:3, and the nucleotide sequence of the antisense strand of the siRNA-L is shown as SEQ ID NO:4. The siRNA-G and / or the siRNA-L can effectively inhibit the expression of the rabies virus G gene and the L gene, reduce the proliferation of the rabies virus, and can be used as an effective small nucleic acid medicine in the development process of an anti-rabies virus medicine.

The invention provides a real-time fluorescent quantitative PCR (polymerase chain reaction) detection primer, kit and method for novel variant bocavirus, and belongs to the technical field of virus nucleic acid detection. A specific primer is designed and synthesized according to a conserved sequence of a novel variant bocavirus (BoV) VP gene, a recombinant plasmid pcDNA3.1 HA-BoV-VP is constructed, then the recombinant plasmid is used as a standard substance to establish a standard curve, a real-time fluorescent quantitative PCR detection system for the novel variant bocavirus is constructed, and specific detection of the novel variant bocavirus is realized. The detection method can realize quantitative detection of bocavirus in a to-be-detected sample, has the characteristics of high speed, high sensitivity, strong specificity and the like, plays an important role in protection of endangered wild animals such as disc sheep, and has good practicability.

Adeno-associated virus (AAV) gene therapy vectors express a therapeutic protein or RNA that treats a genetic defect in a cell. The present disclosure provides AAV gene therapy vectors that additionally express an anti-inflammatory protein or peptide. When the provided AAV gene therapy vectors are used in methods of treatment of, for example, neurodegenerative diseases, the therapeutic protein / RNA treats the genetic defect within the cells directly transduced by the AAV vectors while the anti-inflammatory protein / peptide is secreted by the transduced cells into the intercellular milieu and treats microglial activation associated with the neuroinflammatory component of the neurodegenerative diseases. The therapeutic protein and anti-inflammatory protein / peptide can be expressed as fusion protein in which the two are separated in the fusion protein by a self-cleaving peptide. The anti-inflammatory protein / peptide can alternatively be expressed from a separate vector from the AAV gene therapy vector. The provided AAV gene therapy vectors and methods are thus useful in treating neurological and neurodegenerative disorders such as Amyotrophic Lateral Sclerosis, Duchenne's Muscular Dystrophy), spinal muscular atrophy, Batten diseases (CLN1 / 3 / 6 / 8), an IGHMBP2-related disorder, and PGAP3 Congenital Disorder of Glycosylation, including the neuroinflammation associated with the disorders.

The application provides an anti-Norovirus GII genotype VP1 antigen monoclonal antibody and an application thereof. The anti-Norovirus GII genotype VP1 antigen monoclonal antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises a heavy chain CDR3 shown in SEQ ID NO. 3, and the light chain variable region comprises a light chain CDR3 shown in SEQ ID NO. 6. The monoclonal antibody is a rabbit-derived monoclonal antibody, the monoclonal antibody has good specificity and high affinity, and solves the problem of a mouse-derived monoclonal antibody in actual application. The anti-Norovirus GII genotype VP1 antigen monoclonal antibody has important application value in the preparation of a product for detecting Norovirus.

The invention relates to the technical field of molecular biology and virus detection, in particular to an eel herpesvirus detection system, a detection kit, a detection method and application thereof, and the system comprises an RAA amplification system and a CRISPR / AsCas12f1 detection system; the RAA amplification system is used for isothermal amplification of an eel herpesvirus ORF95 gene segment; and the CRISPR / AsCas12f1 detection system is used for identifying an RAA amplification product and generating a fluorescence signal. Through combination of RAA amplification and CRISPR / AsCas12f1 detection, rapid, sensitive and specific detection of AngHV is realized, and the kit is suitable for on-site rapid detection of eel farms and aquatic quarantine departments.

Disclosed is a method of differentiating empty capsids from full capsids or loaded and unloaded non-viral gene therapy vectors in a viral preparation. The method comprises the steps of: a) providing a preparation of viral particles or gene therapy vectors; b) subjecting the preparation to interferometric scattering mass cytometry (ISCAMS) in an interferometric scattering microscope to generate mass distribution data of the viral particles; c) determining from the mass distribution data the level of empty capsids and capsids containing genomes or the level of loaded and unloaded vectors in the viral particles.

The present application relates to bovine tuberous skin disease virus, in particular, to bovine tuberous skin disease virus ORF145 gene deletion strain and its application. The gene deletion strain is characterized in that it is constructed by deleting ORF145 gene from bovine tuberous skin disease virus virulent strain LSDV XJ201901. Compared with the parent strain, the replication level of the constructed deletion strain rLSDVΔ145 in in vitro cells is equivalent to that of the parent strain, indicating that the gene deletion does not affect the in vitro proliferation ability of the virus. In addition, after rLSDVΔ145 infects MDBK cells, it can significantly reduce the mRNA expression level of pro-inflammatory factors IL-1beta and IL-6, while not interfering with the expression of IFNbeta mRNA. Further transcriptomic analysis shows that the deletion strain significantly reduces virulence and pathogenicity on the basis of maintaining good immunogenicity; it not only loses the inhibition ability to the innate immune pathway, but also can effectively activate the adaptive immune response, and significantly reduce the risk of inflammation and tissue damage, showing significant potential as a safe and efficient attenuated live vaccine.